

HB0382/203220/1

BY: Health and Government Operations Committee

AMENDMENTS TO HOUSE BILL 382

(First Reading File Bill)

AMENDMENT NO. 1

On page 1, in the sponsor line, strike “**Delegate Kipke**” and substitute “**Delegates Kipke, Alston, Bagnall, Bhandari, Chisholm, Cullison, Guzzone, Hill, Hutchinson, S. Johnson, Kaiser, Kerr, R. Lewis, Lopez, Martinez, M. Morgan, Pena–Melnik, Reilly, Rosenberg, Szeliga, Taveras, White, and Woods**”; strike beginning with “**Pharmacy**” in line 2 down through “**Managers**” in line 3 and substitute “**Maryland Department of Health and Prescription Drug Affordability Board – Managed Care Organizations and Prescription Drug Claims – Study**”; strike beginning with “altering” in line 4 down through “organizations” in line 10 and substitute “**requiring the Maryland Department of Health and the Prescription Drug Affordability Board jointly to study certain information regarding the payment of prescription drug claims under the Maryland Medical Assistance Program during certain calendar years and how to address certain inconsistencies**”; and in line 10, strike “pharmacy benefits administration” and substitute “**managed care organizations and the payment of prescription drug claims**”.

On pages 1 and 2, strike in their entirety the lines beginning with line 11 on page 1 through line 3 on page 2, inclusive.

AMENDMENT NO. 2

On page 2, in line 5, strike “the Laws of Maryland read as follows”.

On pages 2 and 3, strike in their entirety the lines beginning with line 6 on page 2 through line 24 on page 3, inclusive, and substitute:

HB0382/203220/01 Health and Government Operations Committee
Amendments to HB 382
Page 2 of 2

“(a) The Maryland Department of Health and the Prescription Drug Affordability Board jointly shall study:

(1) (i) the total amount the managed care organizations in the State paid pharmacies for prescription drug claims in calendar years 2021 and 2022; and

(ii) what the total amount paid to pharmacies would have been, in calendar years 2021 and 2022, if the prescription drug claims had been reimbursed at the Maryland Medical Assistance Program fee-for-service rates; and

(2) how to best address the inconsistency in the amounts studied under item (1) of this subsection by:

(i) considering the total cost to the State; and

(ii) recommending a methodology for determining the most accurate ingredient cost of a drug and an appropriate dispensing fee.

(b) On or before October 31, 2023, the Maryland Department of Health and the Prescription Drug Affordability Board jointly shall report its findings to the Maryland Medicaid Administration and, in accordance with § 2-1257 of the State Government Article, the Senate Budget and Taxation Committee, the Senate Finance Committee, the House Appropriations Committee, and the House Health and Government Operations Committee.”.